Aberdeen Group plc Acquires 372,207 Shares of Immatics N.V. $IMTX

Key Points

• Aberdeen Group plc increased its stake in Immatics N.V. by **107.1%** in the first quarter, owning **719,586 shares** worth approximately **$3.25 million** after purchasing an additional **372,207 shares**.
• Several large investors also reinvested in Immatics, with Suvretta Capital Management LLC acquiring a new position valued at around **$36 million** and T. Rowe Price boosting its position by **43.7%**.
• Immatics reported an earnings miss for the last quarter with an EPS of **($0.66)**, falling short of the estimated **($0.38)**, alongside a revenue of **$6.48 million**, significantly below expectations.

Aberdeen Group plc boosted its holdings in shares of Immatics N.V. (NASDAQ:IMTX - Free Report) by 107.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 719,586 shares of the company's stock after acquiring an additional 372,207 shares during the period. Aberdeen Group plc owned 0.59% of Immatics worth $3,245,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of IMTX. Guggenheim Capital LLC acquired a new stake in Immatics during the 4th quarter worth $101,000. Marshall Wace LLP acquired a new position in shares of Immatics in the 4th quarter valued at $409,000. T. Rowe Price Investment Management Inc. grew its holdings in shares of Immatics by 43.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock valued at $75,400,000 after buying an additional 3,225,141 shares during the period. Virtus ETF Advisers LLC grew its holdings in shares of Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after buying an additional 2,479 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Immatics by 31.5% in the 4th quarter. Northern Trust Corp now owns 47,226 shares of the company's stock valued at $336,000 after buying an additional 11,304 shares during the period. Institutional investors and hedge funds own 64.41% of the company's stock.

Immatics Price Performance

NASDAQ:IMTX traded up $0.12 on Tuesday, hitting $5.35. 973,720 shares of the company's stock were exchanged, compared to its average volume of 605,186. The firm has a 50-day moving average price of $5.97 and a 200-day moving average price of $5.20. Immatics N.V. has a 52 week low of $3.30 and a 52 week high of $13.09. The company has a market cap of $650.29 million, a P/E ratio of -8.23 and a beta of 0.93.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.The business had revenue of $6.48 million for the quarter, compared to the consensus estimate of $13.05 million. On average, research analysts expect that Immatics N.V. will post -0.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on IMTX shares. Zacks Research lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. Wall Street Zen lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Immatics in a report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.67.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.